It’s highly accepted in the medical field that type 2 diabetes is a risk factor for Alzheimer’s Disease (AD). But less accepted is the new theory of type 3 diabetes. This is a term which describes the hypothesis that Alzheimer’s disease may be triggered by insulin resistance and insulin-like growth factor dysfunction that occurs in the brain.
Study reports modifying twelve risk factors over your lifetime could reduce dementia risk by 40%.
Alzheimer’s risk factors could be apparent as early as our teenage years, researchers reports. The risk factors disproportionately affect African Americans and include heart health problems, high cholesterol, diabetes, and insufficient quality of education.
For the first time, an intervention – lifting weights – has been able to slow and even halt degeneration, over a long period, in brain areas particularly vulnerable to Alzheimer’s disease.
For the first time, dietary flavonols, which are components of many fruits, vegetables, and tea, have been linked to a significantly lower risk of developing Alzheimer disease (AD). However, some experts are calling for healthy skepticism when interpreting the findings.
I tried to kill my father for years. To be fair, I was following his wishes. He’d made it clear that when he no longer recognized me, when he could no longer talk, when the nurses started treating him like a toddler, he didn’t want to live any longer.
Over a third of people would want to know they had Alzheimer’s disease 15 years before symptoms show, according to new findings from Alzheimer’s Research UK.
We’ve heard from Alzheimer’s caregivers and patients that they want a way to navigate the disease and to plan for the future.
Staying aerobically fit, and sticking to an exercise routine like running, is good for your brain and overall health. But new research points towards yoga as another option for those who want to protect their brains from Alzheimer’s — and who may enjoy physical activity that’s a bit more calm.
After a string of drug failures, researchers are looking beyond amyloid as a target